[Development and Validation of A Prognostic Nomogram to Guide Decision-making  in Lung Large Cell Neuroendocrine Carcinoma]

Overview

Journal Zhongguo Fei Ai Za Zhi

Specialties Oncology
Pulmonary Medicine

Date 2023 Aug 31

PMID 37653012

Authors

Sheng Chen

Shaoxiang Li

Zipeng Wang

Wenxi Zhang

Liang Zhou

Wenjie Jiao

Affiliations

Soon will be listed here.

Abstract

Background: Lung large cell neuroendocrine carcinoma (LCNEC) is a rare and highly malignant lung tumor with a poor prognosis. Currently, most research on LCNEC is based on retrospective studies and lacks validation in the real world. The study aims to identify independent risk factors and establish and validate a predictive model for the prognosis of LCNEC.

Methods: Patient data were extracted from Surveillance, Epidemiology, and End Results (SEER) and our department's hospitalization records from 2010 to 2015 and 2016 to 2020, respectively. Kaplan-Meier analysis was used to evaluate overall survival (OS). OS is defined as the time from diagnosis to death or last follow-up for a patient. Univariate and multivariate Cox regression analyses were performed to identify significant prognostic factors and construct a Nomogram for predicting the prognosis of LCNEC.

Results: In total, 1892 LCNEC patients were included and divided into a training cohort (n=1288) and two validation cohorts (n=552, n=52). Univariate Cox regression analysis showed that age, gender, primary tumor site, laterality, T stage, N stage, M stage, surgery, and radiotherapy were factors that could affect the prognosis of LCNEC patients (P<0.05). Multivariate Cox analysis indicated that age, gender, primary tumor site, T stage, N stage, M stage, surgery, and radiotherapy were independent risk factors for the prognosis of LCNEC patients (P<0.05). Calibration curves and the concordance index (internal: 0.744±0.015; external: 0.763±0.020, 0.832±0.055) demonstrated good predictive performance of the model.

Conclusions: Patients aged ≥65 years, male, with advanced tumor-node-metastasis (TNM) staging, and who have not undergone surgery or radiotherapy have a poor prognosis. Nomogram can provide a certain reference for personalized clinical decision-making for patients.

References

Gu J, Gong D, Wang Y, Chi B, Zhang J, Hu S . The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung. Cancer Med. 2019; 8(6):2979-2993. PMC: 6558599. DOI: 10.1002/cam4.2188. View

Lee H, Lee C, Park Y . Location of stage I-III non-small cell lung cancer and survival rate: Systematic review and meta-analysis. Thorac Cancer. 2018; 9(12):1614-1622. PMC: 6275821. DOI: 10.1111/1759-7714.12869. View

Yang Q, Xu Z, Chen X, Zheng L, Yu Y, Zhao X . Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis. Thorac Cancer. 2019; 10(4):751-760. PMC: 6449250. DOI: 10.1111/1759-7714.12993. View

Qian Z, Hu Y, Zheng H, Dong Y, Wang Q, Li B . [Clinical Analysis of 22 Cases of Pulmonary Large Cell Neuroendocrine Cancer]. Zhongguo Fei Ai Za Zhi. 2016; 19(2):82-7. PMC: 6015146. DOI: 10.3779/j.issn.1009-3419.2016.02.05. View

Derks J, Hendriks L, Buikhuisen W, Groen H, Thunnissen E, van Suylen R . Clinical features of large cell neuroendocrine carcinoma: a population-based overview. Eur Respir J. 2015; 47(2):615-24. DOI: 10.1183/13993003.00618-2015. View

Song Z, Zou L . Risk factors, survival analysis, and nomograms for distant metastasis in patients with primary pulmonary large cell neuroendocrine carcinoma: A population-based study. Front Endocrinol (Lausanne). 2022; 13:973091. PMC: 9623680. DOI: 10.3389/fendo.2022.973091. View

Komiya T, Guddati A, Chaaya G . Overview of publications on lung cancer using the SEER database. Respir Investig. 2018; 56(5):424-426. DOI: 10.1016/j.resinv.2018.06.005. View

Sarkaria I, Iyoda A, Roh M, Sica G, Kuk D, Sima C . Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. Ann Thorac Surg. 2011; 92(4):1180-6. DOI: 10.1016/j.athoracsur.2011.05.027. View

Chen K, Dai P, Ni J, Xiang Y, Gu L . The prognosis analysis of organ metastatic patterns in lung large cell neuroendocrine carcinoma: A population-based study. Front Oncol. 2022; 12:1050800. PMC: 9773085. DOI: 10.3389/fonc.2022.1050800. View

10.

Rocha A, McCormack M, Montana G, Schreiber G . Association between lower lobe location and upstaging for early-stage non-small cell lung cancer. Chest. 2004; 125(4):1424-30. DOI: 10.1378/chest.125.4.1424. View

11.

Wakeam E, Adibfar A, Stokes S, Leighl N, Giuliani M, Varghese Jr T . Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg. 2019; 159(5):2043-2054.e9. DOI: 10.1016/j.jtcvs.2019.09.077. View

12.

Ganti A, Loo B, Bassetti M, Blakely C, Chiang A, DAmico T . Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(12):1441-1464. PMC: 10203822. DOI: 10.6004/jnccn.2021.0058. View

13.

Zhang J, Li Y, Yan L, Zhu Z, Dong X, Chu Q . Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. Lung Cancer. 2019; 139:118-123. DOI: 10.1016/j.lungcan.2019.11.004. View

14.

Kim H, Choi C, Kim S . The Younger Patients Have More Better Prognosis in Limited Disease Small Cell Lung Cancer. Tuberc Respir Dis (Seoul). 2016; 79(4):274-281. PMC: 5077731. DOI: 10.4046/trd.2016.79.4.274. View

15.

Kinslow C, May M, Saqi A, Shu C, Chaudhary K, Wang T . Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study. Clin Lung Cancer. 2019; 21(2):e99-e113. DOI: 10.1016/j.cllc.2019.07.011. View

16.

Liu C, Tao Y . Based on SEER Database: Population Distribution, Survival Analysis, and Prognostic Factors of Organ Metastasis of Lung Large Cell Neuroendocrine Carcinoma. Front Oncol. 2022; 12:810170. PMC: 8971719. DOI: 10.3389/fonc.2022.810170. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Khan J, Yasinzai A, Matosz S, Khan M, Heneidi S, Mesa H . Pulmonary large cell neuroendocrine carcinoma (LCNEC): a population-based study addressing recent molecular-genetic advances and emerging therapeutic approaches. Clin Exp Med. 2023; 23(7):3947-3955. DOI: 10.1007/s10238-023-01071-8. View

19.

He Y, Liu H, Wang S, Chen Y . Prognostic nomogram predicts overall survival in pulmonary large cell neuroendocrine carcinoma. PLoS One. 2019; 14(9):e0223275. PMC: 6764685. DOI: 10.1371/journal.pone.0223275. View

20.

Cao L, Wu H, Zhao L, Bai Y, Jiang Z, Yang W . The role of radiotherapy in pulmonary large cell neuroendocrine carcinoma: propensity score matching analysis. J Radiat Res. 2020; 61(4):594-601. PMC: 7336819. DOI: 10.1093/jrr/rraa036. View

[Development and Validation of A Prognostic Nomogram to Guide Decision-making in Lung Large Cell Neuroendocrine Carcinoma]

[Development and Validation of A Prognostic Nomogram to Guide Decision-making  in Lung Large Cell Neuroendocrine Carcinoma]